Cure My Disease

Don't miss your cure!

 Log in / Sign up

New targeted radiation shows promise for Tough-to-Treat prostate cancer

NCT ID NCT06526299

Recruiting now Disease control Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Nov 05, 2025 · Last updated May 15, 2026 · Updated 25 times

Summary

This study tests a drug called 177Lu-PSMA-617 in 51 men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug delivers a small dose of radiation directly to cancer cells to damage their DNA. The goal is to see if it can slow cancer growth and improve outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Olive View-University of California Los Angeles Medical Center

    NOT_YET_RECRUITING

    Sylmar, California, 91342, United States

    Contact

  • University of California San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

    Contact

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA STAGE IVB PROSTATE CANCER AJCC V8 STAGE IVB PROSTATE CANCER AJCC V8